Newamsterdam Pharma Co NV

NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company, which engages in the development of oral, non-statin medicine for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol. Its lead product candidate, Obicetrapib, is a next-generation, oral, low-dose cholesteryl ester transfer protein inhibitor, which will be used to prevent major adverse cardiovascular events. The company was founded on June 10, 2022 and is headquartered in Naarden, the Netherlands.

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

-- Observed reductions of 11% and 12% in 24- and 27-hydroxycholesterol in cerebrospinal fluid (“CSF”), respectively, indicating potential improvement of cholesterol metabolism in the brain -- -- Observed 8% increase in Aβ42/40 ratio, a key biomarker of AD risk, suggesting improvement in disease pathology -- NAARDEN, The Netherlands and MIAMI, Sept. 21, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a clinical-stage biopharmaceutical company developing oral, non-statin medicines for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced initial data from its Phase 2a clinical trial evaluating obicetrapib in patients with early Alzheimer's disease (“AD”) and at least one copy of the apolipoprotein E4 mutation (“ApoE4”).

NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer's Disease Who Carry an ApoE4 Mutation

NAARDEN, The Netherlands and MIAMI, Sept. 20, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma” or the “Company”), a clinical-stage biopharmaceutical company developing oral, non-statin medicines for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that Michael Davidson, M.D., chief executive officer of NewAmsterdam Pharma, will participate in a fireside chat at the 2023 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 27, 2023 at 1:50 p.m. ET.

NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference

NewAmsterdam Pharma showcased positive trajectory in Q2 2023 financial report, with over-enrollment in obicetrapib's Ph.3 BROADWAY trial indicating robust global demand. Lead asset obicetrapib is set to present top-line data in 2H24, with potential approval by 2025-2026. Obicetrapib is a novel oral LDL-c lowering treatment that can be taken with statins and ezetimibe, which we believe to have a peak sales of ~$2bn.

NewAmsterdam Pharma: Best Cardiovascular Biotech In 2023

NAARDEN, The Netherlands and MIAMI, Aug. 14, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a clinical-stage biopharmaceutical company developing oral, non-statin medicines for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointment of William “BJ” Jones as the Company's first Chief Commercial Officer (“CCO”), effective August 14, 2023. Mr. Jones brings 30 years of commercial and launch experience in the U.S. and globally, with particular experience in driving mass market product launch strategies for industry-leading brands. At NewAmsterdam, he will build and lead all commercial functions, including marketing, market access, sales, medical science engagement and commercial operations.

NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer

-- Announced full data from ROSE2 Phase 2 clinical trial evaluating combination of obicetrapib and ezetimibe, which met the primary endpoint with 63.4% median reduction in LDL-C (p

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights

-- Exceeded Target Enrollment; Expect to Randomize More Than 2,500 Patients -- -- Topline Results Expected in 2H 2024 –

NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular Disease

NAARDEN, The Netherlands and MIAMI, June 09, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a clinical-stage biopharmaceutical company developing oral, non-statin medicines for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol, for whom existing therapies are not sufficiently effective or well-tolerated, today announced the closing of the previously announced underwritten public offering of 15,787,695 of the Company's ordinary shares, with a nominal value of €0.12 per share (“Ordinary Shares,” such offering, the “Offering”) by certain of the Company's existing shareholders, including affiliates of Forbion (collectively, the “Selling Shareholders”), at a public offering price of $11.50 per share, which included a partial exercise of the underwriters' option to purchase additional Ordinary Shares, granted to the underwriters by certain of the Selling Shareholders. The Company did not receive any proceeds from the Offering.

NewAmsterdam Pharma Announces Closing of Upsized Secondary Offering of Ordinary Shares

NewAmsterdam Pharma Company N.V. (NAMS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.

After Plunging -16.36% in 4 Weeks, Here's Why the Trend Might Reverse for NewAmsterdam Pharma Company N.V. (NAMS)

NewAmsterdam is a clinical-stage biopharmaceutical company with a lead therapy candidate that lowers cholesterol levels. The company is examining the therapy to treat high cholesterol levels on patients with cardiovascular disease as well as on Alzheimer's patients.

Why Shares of NewAmsterdam Pharma Were Plummeting on Wednesday

NAARDEN, The Netherlands and MIAMI, June 06, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a clinical-stage biopharmaceutical company developing oral, non-statin medicines for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol, for whom existing therapies are not sufficiently effective or well-tolerated, today announced the pricing of the previously announced underwritten public offering of 13,857,415 shares of the Company's ordinary shares, with a nominal value of €0.12 per share (“Ordinary Shares,” such offering, the “Offering”) by certain of the Company's existing shareholders, including affiliates of Forbion Capital Partners (collectively, the “Selling Shareholders”), at a public offering price of $11.50 per share. In connection with the Offering, certain of the Selling Shareholders have granted the underwriters a 30-day option to purchase up to an additional 2,078,612 Ordinary Shares at the public offering price, less the underwriting discount. The Offering is expected to close on or about June 9, 2023, subject to customary closing conditions. The Company will not receive any proceeds from the Offering.

NewAmsterdam Pharma Announces Pricing of Upsized Secondary Offering of Ordinary Shares

NAARDEN, the Netherlands and MIAMI, June 06, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a clinical-stage biopharmaceutical company developing oral, non-statin medicines for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol, for whom existing therapies are not sufficiently effective or well-tolerated, today announced the commencement of an underwritten public offering of 10,579,210 of the Company's ordinary shares, with a nominal value of €0.12 per share (“Ordinary Shares,” such offering, the “Offering”), by certain of the Company's existing shareholders affiliated with Forbion Capital Partners. The Company will not receive any proceeds from the proposed Offering.

NewAmsterdam Pharma Announces Commencement of Secondary Offering of Ordinary Shares

-- Achieved Primary Endpoint with Statistically Significant 45.8% Median Reduction in LDL-C (p < 0.0001) in patients treated with 10mg obicetrapib-- -- 29.7% Median Reduction in Apo B and 37.0% Median Reduction in non-HDL-C from Baseline (p < 0.0001) in patients treated with 10mg obicetrapib --

NewAmsterdam Pharma Announces Positive Topline Results from Phase 2b Dose-Finding Trial Evaluating Obicetrapib in Japanese Patients

– Met Primary Endpoint with 63.4% Median Reduction in LDL-C (p

NewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023

NewAmsterdam to review data on webcast conference call on June 5, 2023 at 8:00 a.m. ET NewAmsterdam to review data on webcast conference call on June 5, 2023 at 8:00 a.m. ET

NewAmsterdam to Present Full Data from ROSE2 at NLA Scientific Sessions 2023

Replimune Group Inc

Dualyx r aises € 40 m illion to progress Treg therapies for autoimmune diseases into the clinic

Dualyx raises €40 million to progress Treg therapies for autoimmune diseases into the clinic

-- Completed enrollment in BROOKLYN Phase 3 clinical trial evaluating obicetrapib in patients with heterozygous familial hypercholesterolemia (“HeFH”) ahead of schedule; topline results expected in 2H 2024 -- -- Announced positive topline results in January 2023 and scheduled to present full data from ROSE2 Phase 2 clinical trial evaluating combination of obicetrapib and ezetimibe at the National Lipid Association (“NLA”) Scientific Sessions in June 2023 --

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Highlights

-- Enrollment Completed Several Months Ahead of Schedule, Reflecting Significant Unmet Need and Patient Demand for New Options -- -- Topline Results Expected in 2H 2024 –

NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia

NAARDEN, the Netherlands and MIAMI, April 03, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma” or the “Company”), a clinical-stage company focused on the research and development of transformative oral therapies for major cardiometabolic diseases, today announced the appointment of Janneke van der Kamp as an independent director to its Board of Directors. Ms. van der Kamp is an established pharmaceutical leader, with two decades of experience launching and growing key brands across several therapeutic areas, including cardiovascular disease.

NewAmsterdam Pharma Appoints Janneke van der Kamp to its Board of Directors

NAARDEN, The Netherlands and MIAMI, March 31, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a clinical-stage company focused on the research and development of transformative oral therapies for major cardiometabolic diseases, today announced its financial results for the full year ended December 31, 2022 and provided a corporate update.

NewAmsterdam Pharma Reports Full Year 2022 Financial Results and Provides Corporate Update

NewAmsterdam Pharma is a Dutch SMID cap biotech focusing on cardiovascular diseases. NewAmsterdam Pharma has a promising pipeline drug called Obicetrapib that has shown significant potential for LDL-C and apoB lowering.

NewAmsterdam: An Underfollowed Dutch Biotech Cardiovascular Biotech

Eli Lilly

Cassava Sciences Inc

One in every nine seniors is living with Alzheimer's disease, and the race to cure it is worth big money. While the FDA has approved some Alzheimer's disease drugs, these can only slow the progression, not halt or reverse it.

3 Drug Stocks to Watch as Alzheimer's Clinical Trials End

NAARDEN, the Netherlands and MIAMI, Feb. 09, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma” or the “Company”), a clinical-stage company focused on the research and development of transformative oral therapies for major cardiometabolic diseases, today announced that Michael Davidson, M.D., chief executive officer of NewAmsterdam Pharma, will present at SVB Securities Global Biopharma Conference on Thursday, February 16, 2023 at 1:00 p.m. ET.

NewAmsterdam Pharma to Present at the SVB Securities Global BioPharma Conference

NAARDEN, The Netherlands and MIAMI, Feb. 06, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma” or the “Company”), a clinical-stage company focused on the research and development of transformative oral therapies for major cardiometabolic diseases, today announced the appointment of John W. Smither as an independent director to its Board of Directors. Mr. Smither will also serve as chair of NewAmsterdam Pharma's Audit Committee.

NewAmsterdam Pharma Appoints John W. Smither to its Board of Directors

Frazier Lifesciences Acquisition Corp

-- Business combination transaction with Frazier Lifesciences Acquisition Corporation, a special purpose acquisition company sponsored by an affiliate of Frazier Healthcare Partners, completed on November 22, 2022 -- -- Closed concurrent, oversubscribed and upsized approximately $235 million private investment in public equity (“PIPE”), led by Frazier Healthcare Partners and Bain Capital Life Sciences --

NewAmsterdam Pharma Debuts as Publicly Traded Company Focused on Developing Obicetrapib, a Low-Dose, Once-Daily Oral LDL-Lowering Agent with Promising Safety and Efficacy Clinical Data, as a Potential Preferred Therapy for High Risk Cardiovascular Disease

News for Newamsterdam Pharma Co NV Stock (NAMS)